Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Comparison of st-segment resolution with combined fibrinolytic and glycoprotein iib/iiia inhibitor therapy versus fibrinolytic alone (data from four clinical trials)

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Rebeiz, A. G.
  • Johanson, P.
  • Green, C. L.
  • Crater, S. W.
  • Roe, M. T.
  • Langer, A.
  • Giugliano, R. P.
  • Lincoff, A. M.
  • Newby, L. K.
  • Harrington, R. A.
  • Topol, Eric
  • Califf, R. M.
  • Wagner, G. S.
  • Krucoff, M. W.

publication date

  • March 2005

journal

  • American Journal of Cardiology  Journal

abstract

  • We compared combination fibrinolytic plus glycoprotein IIb/IIIa inhibitor therapy with stand-alone fibrinolysis with respect to speed and stability of reperfusion in patients who had acute ST-segment elevation myocardial infarction; data were obtained from 654 patients in 4 trials (Integrilin to Manage Platelet Aggregation to Combat Thrombosis in Acute Myocardial Infarction, Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction, Integrilin and Tenecteplase in Acute Myocardial Infarction, and the Fifth Global Use of Strategies to Open Occluded Coronary Arteries) that compared thrombolytics plus lamifiban, eptifibatide, or abciximab with standard thrombolysis. We found significantly faster and more stable ST-segment recovery with combination therapy starting at 60 minutes (56.7% vs 48.0% with >/=50% ST-segment resolution, p = 0.03) and sustained over 180 minutes after drug administration; this transient benefit may suggest a time frame when more optimal percutaneous coronary intervention can be performed.

subject areas

  • Acetates
  • Aged
  • Antibodies, Monoclonal
  • Clinical Trials as Topic
  • Drug Therapy, Combination
  • Electrocardiography
  • Female
  • Humans
  • Immunoglobulin Fab Fragments
  • Male
  • Middle Aged
  • Myocardial Infarction
  • Peptides
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Streptokinase
  • Survival Analysis
  • Thrombolytic Therapy
  • Tissue Plasminogen Activator
  • Treatment Outcome
  • Tyrosine
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0002-9149

Digital Object Identifier (DOI)

  • 10.1016/j.amjcard.2004.10.038

PubMed ID

  • 15721101
scroll to property group menus

Additional Document Info

start page

  • 611

end page

  • 614

volume

  • 95

issue

  • 5

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support